Market Overview

Stifel Terminates Coverage On Oncolytics Biotech Due To Reallocation Of Resources

Share:

In a report published Monday, Stifel analyst Brian Klein terminated coverage on Oncolytics Biotech (NASDAQ: ONCY).

In the report, Stifel noted, "Due to a reallocation of resources, we are discontinuing coverage of Oncolytics Biotech Inc. (ONCY). Our most recent rating of Hold should no longer be used as an indicator for the company going forward."

Oncolytics Biotech closed on Friday at $0.42.

Latest Ratings for ONCY

DateFirmActionFromTo
Sep 2013Initiates Coverage onBuy
Mar 2013Initiates Coverage onOverweight
Dec 2012DowngradesBuyHold

View More Analyst Ratings for ONCY
View the Latest Analyst Ratings

Posted-In: Brian Klein StifelAnalyst Color Termination Analyst Ratings

 

Related Articles (ONCY)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
FDXMaintains175.0
ITWDowngrades121.0
CSTRDowngrades
CRCMDowngrades
JRVRMaintains40.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Citigroup Initiates AbbVie With Sell

Stifel Terminates Coverage On GTx Due To Reallocation Of Resources